Endocrinology · PANCE / PANRE

Type 1 Diabetes Mellitus

Autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency.

Also known as: T1DM, type 1 diabetes, insulin-dependent diabetes, juvenile diabetes, IDDM

Overview

Chronic autoimmune disease characterized by T-cell mediated destruction of pancreatic islet beta cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin to prevent ketoacidosis and death.

Epidemiology

Accounts for ~5-10% of all diabetes. Bimodal peak incidence at age 4-7 and 10-14 years, but can present at any age (including LADA in adults). Higher prevalence in non-Hispanic whites, Scandinavian populations. Strong HLA association (HLA-DR3, HLA-DR4).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Type 1 Diabetes Mellitus outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Genetic: HLA-DR3/DR4-DQ8 haplotypes (highest risk), family history (5-10% if first-degree relative)
  • Environmental triggers: enteroviral infection (coxsackie B), early cow's milk exposure, vitamin D deficiency
  • Other autoimmune disease: Hashimoto thyroiditis, celiac disease, Addison disease, pernicious anemia (polyglandular syndrome type 2)

Pathophysiology

Autoreactive T cells infiltrate pancreatic islets (insulitis) and selectively destroy insulin-producing beta cells. Clinical hyperglycemia emerges when ~80-90% of beta-cell mass is lost. Absolute insulin deficiency leads to unopposed glucagon action, hepatic gluconeogenesis, lipolysis, and ketogenesis. Without insulin, patients cannot suppress ketone production and are at risk for DKA.

Clinical presentation

Symptoms

  • Classic triad: polyuria, polydipsia, polyphagia
  • Unintentional weight loss despite normal or increased intake
  • Fatigue, weakness, blurred vision
  • May present with DKA as initial manifestation (~30% of pediatric cases): nausea, vomiting, abdominal pain, Kussmaul respirations, altered mental status

Signs / physical exam

  • Often thin or recent weight loss; not obese
  • Dehydration: dry mucous membranes, decreased skin turgor, tachycardia
  • Fruity (acetone) breath in DKA
  • Kussmaul (deep, rapid) respirations in DKA

Classic findings

Lean young patient with rapid onset of polyuria, polydipsia, weight loss, sometimes presenting in DKA.

Differential diagnosis

  • Type 2 diabetes mellitus — Older onset, obesity, acanthosis nigricans, family history, gradual onset; insulin resistance with relative deficiency; negative autoantibodies; C-peptide preserved
  • Latent autoimmune diabetes of adults (LADA) — Adult onset (>30), initial response to oral agents then rapid progression to insulin; positive GAD-65 antibodies; slow autoimmune destruction
  • MODY (maturity-onset diabetes of the young) — Autosomal dominant family history across 3 generations; onset <25; non-obese; no autoantibodies; preserved C-peptide; HNF1A/glucokinase mutations
  • Secondary diabetes (pancreatic) — History of chronic pancreatitis, pancreatectomy, hemochromatosis, cystic fibrosis; absent C-peptide; pancreatic exocrine insufficiency
  • Drug-induced diabetes — Glucocorticoids, tacrolimus, atypical antipsychotics (olanzapine, clozapine), HIV protease inhibitors, thiazides
  • Stress hyperglycemia — Transient elevation during acute illness, sepsis, or trauma in patient without prior diabetes; resolves with recovery

Diagnostic workup

Diagnostic criteria

ADA criteria: A1c ≥6.5%, fasting glucose ≥126 mg/dL, 2-hr OGTT ≥200 mg/dL, or random ≥200 mg/dL with symptoms. T1DM confirmed by positive autoantibodies and/or low C-peptide.

Labs

  • Fasting plasma glucose ≥126 mg/dL on 2 occasions, OR random glucose ≥200 mg/dL with symptoms, OR A1c ≥6.5%, OR 2-hour OGTT ≥200 mg/dL
  • Islet autoantibodies (≥1 positive confirms T1DM): GAD-65, IA-2, insulin autoantibodies (IAA), ZnT8
  • C-peptide (low or undetectable) — differentiates from T2DM
  • TSH, TPO antibodies, tissue transglutaminase IgA (screen for associated autoimmune disease)
  • BMP, urine ketones, blood gas if DKA suspected

Imaging

  • Not routinely needed for diagnosis
  • Dilated retinal exam at diagnosis and annually thereafter

Diagnostic algorithm

FeatureType 1 DMType 2 DM
Age of onsetUsually <30 (any age possible)Usually >40 (increasing in youth)
Body habitusLean or normal weightOverweight/obese (~80%)
OnsetAcute (weeks); may present with DKAInsidious (months-years)
PathophysiologyAutoimmune beta-cell destructionInsulin resistance + relative deficiency
AutoantibodiesPositive (GAD-65, IA-2, IAA, ZnT8)Negative
C-peptideLow or undetectableNormal or elevated (early)
Ketosis-proneYes (absolute insulin deficiency)Rare (except HHS or severe stress)
First-line treatmentInsulin (lifelong)Lifestyle + metformin
HLA associationHLA-DR3/DR4-DQ8None
Family history5-10% in first-degree relativesStrong (40% lifetime risk if both parents)
Comparison of Type 1 vs Type 2 Diabetes Mellitus.

Treatment

First-line

  • Lifelong exogenous insulin — basal-bolus regimen mimicking physiologic secretion
  • Long-acting basal insulin: glargine (Lantus, Basaglar, Toujeo), detemir, degludec (Tresiba) — once daily
  • Rapid-acting prandial insulin: lispro (Humalog), aspart (Novolog), glulisine (Apidra) — at meals based on carb counting
  • Insulin pump therapy (CSII) with rapid-acting insulin — alternative to multiple daily injections
  • Continuous glucose monitor (CGM): Dexcom G6/G7, Freestyle Libre — strongly recommended
  • Carbohydrate counting and insulin-to-carb ratio education

Second-line / adjunct

  • Closed-loop / hybrid closed-loop systems (Tandem Control-IQ, Medtronic 780G, Omnipod 5) — automated insulin delivery
  • Pramlintide (amylin analog) — adjunct to mealtime insulin in selected patients
  • Pancreas or islet cell transplant — reserved for refractory hypoglycemia unawareness or end-stage renal disease requiring kidney transplant

Complications

  • Acute: DKA, hypoglycemia (especially with intensive insulin therapy), hypoglycemia unawareness
  • Microvascular: retinopathy, nephropathy, neuropathy (peripheral, autonomic)
  • Macrovascular: CAD, stroke, peripheral arterial disease
  • Infections: foot ulcers, recurrent UTIs, mucormycosis (in DKA)
  • Psychosocial: eating disorders (diabulimia — insulin omission for weight loss), depression

PANCE pearls

  • Honeymoon phase: transient partial remission after diagnosis with reduced insulin requirements; insulin needs return as residual beta cells fail.
  • Dawn phenomenon: early morning hyperglycemia from nocturnal growth hormone and cortisol surge; treat by adjusting basal insulin timing.
  • Somogyi effect: rebound hyperglycemia after nocturnal hypoglycemia (controversial in modern practice with CGM data).
  • Always check for DKA in any T1DM patient with acute illness, vomiting, or hyperglycemia >250 mg/dL.
  • Sick-day rules: never stop insulin; check ketones; increase frequency of glucose monitoring; maintain hydration.

References

  • ADA 2025 — American Diabetes Association Standards of Care in Diabetes—2025 (Diabetes Care 2025; 48 Suppl 1)
  • DCCT/EDIC — The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in IDDM (DCCT Research Group, NEJM 1993)
  • ISPAD 2022 — ISPAD Clinical Practice Consensus Guidelines 2022 — Type 1 Diabetes in Children and Adolescents

Practice Endocrinology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.